Q-omics provides the consensus-scored DDX18P6 profile across patient tissues and cancer cell-line models. DDX18P6 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DDX18P6 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, DDX18P6 RNA expression shows 6,394 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, COAD, and STAD as cancer lineages where DDX18P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX18P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX18P6 survival associations across molecular data types. DDX18P6 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX18P6 RNA expression–survival associations across cancer types. High DDX18P6 expression shows unfavorable associations in STAD, MESO, ACC and THYM, but favorable associations in HNSC and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify HNSC as the clearest survival context for DDX18P6 RNA expression.
This table summarizes DDX18P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for DDX18P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX18P6 shows lower tumor expression in KICH and higher tumor expression in COAD and LUAD. The COAD box plot shows higher DDX18P6 RNA expression in tumor versus normal tissue (log2 FC = +0.038, t-test p = .020).
This table shows molecular features associated with DDX18P6 in patient tissues and cancer cell lines. In patient samples, DDX18P6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
